Table 1.
Baseline characteristics per age group
| Characteristics | Age at enrolment |
P-value | |
|---|---|---|---|
| <65 years (n = 13 840) | ≥65 years (n = 5084) | ||
| Age (years), mean (SD) | 54.2 (6.3) | 70.5 (4.7) | <0.0001 |
| Women, n (%) | 2948 (21.3) | 1814 (35.7) | <0.0001 |
| Race, n (%) | <0.0001 | ||
| White | 10 886 (78.7) | 4138 (81.4) | |
| Asian | 384 (2.8) | 89 (1.8) | |
| Black | 1894 (13.7) | 604 (11.9) | |
| Other | 673 (4.9) | 253 (5.0) | |
| Region of enrolment, n (%) | <0.0001 | ||
| Central and Eastern Europe | 3909 (28.2) | 1528 (30.1) | |
| Western Europe | 3073 (22.2) | 1102 (21.7) | |
| Canada or USA | 2099 (15.2) | 772 (15.2) | |
| Latin America | 1813 (13.1) | 775 (15.2) | |
| Asia | 1733 (12.5) | 560 (11.0) | |
| Rest of World | 1213 (8.8) | 347 (6.8) | |
| Medical history before index ACS, n (%) | |||
| Hypertension | 8390 (60.6) | 3859 (75.9) | <0.0001 |
| Diabetes mellitus | 3787 (27.4) | 1657 (32.6) | <0.0001 |
| Current tobacco smoker | 3973 (28.7) | 587 (11.5) | <0.0001 |
| Family history of premature coronary heart disease | 5248 (37.9) | 1525 (30.0) | <0.0001 |
| Myocardial infarction | 2499 (18.1) | 1134 (22.3) | <0.0001 |
| Percutaneous coronary intervention | 2212 (16.0) | 1029 (20.2) | <0.0001 |
| CABG | 582 (4.2) | 465 (9.1) | <0.0001 |
| Stroke | 337 (2.4) | 274 (5.4) | <0.0001 |
| Peripheral artery disease | 428 (3.1) | 331 (6.5) | <0.0001 |
| Congestive heart failure | 1800 (13.0) | 1014 (19.9) | <0.0001 |
| Index ACS, n (%) | n = 13 818 | n = 5075 | <0.0001 |
| STEMI | 5039 (36.4) | 1497 (29.4) | |
| Non-STEMI | 6422 (46.4) | 2753 (54.2) | |
| Unstable angina | 2357 (17.0) | 825 (16.2) | |
| PCI or CABG for index ACS, n (%) | 10 201 (73.7) | 3475 (68.4) | <0.0001 |
| Time from index ACS to randomization (months), mean (SD) | 3.6 (2.8) | 3.8 (2.8) | 0.0003 |
| Body mass index (kg/m2), mean (SD) | 28.8 (4.9) | 27.8 (4.6) | <0.0001 |
| Renal function | |||
| eGFR (mL/min), mean (SD) | 83.1 (18.5) | 70.2 (18.2) | <0.0001 |
| eGFR <60 mL/min, n (%) | 1163 (8.4) | 1377 (27.1) | <0.0001 |
| Lipid-lowering drugs at randomization, n (%) | <0.0001 | ||
| High-intensity atorvastatin/rosuvastatin | 12 565 (90.8) | 4246 (83.5) | |
| Atorvastatin 80 mg or rosuvastatin 40 mg | 4058 (29.3) | 1121 (22.0) | |
| Atorvastatin 40 mg or rosuvastatin 20 mg | 8507 (61.5) | 3125 (61.5) | |
| Low- or moderate-intensity atorvastatin/rosuvastatin | 1027 (7.4) | 580 (11.4) | |
| Other statin | 26 (0.2) | 20 (0.4) | |
| No statin | 222 (1.6) | 238 (4.7) | |
| Ezetimibe | 408 (2.9) | 142 (2.8) | 0.57 |
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.